Intestinal metaplasia has overexpressions of COX-2.
Short-term 8-week celecoxib, a selective COX-2 inhibitor, exerts a preliminary hint to improve regression in part for persistent Intestinal metaplasia after Helicobacter pylori eradication.
Dr Bor-Shyang Sheu and colleagues validated whether or not a prolonged duration of celecoxib of up to 1 year can be safe and effective.
The research team evaluated 140 patients, with persistent IIntestinal metaplasia after H. pylori eradication for 1 year.
Half of the patients were included with half of them receiving celecoxib 200 mg/day for 12 months and the other half serving as controls.
The team of doctors reported that each patient received serial checkups of blood creatinine levels every 4 months.
After the 1-year follow-up, panendoscopy was repeated to assess the intestinal metaplasia regression.
The research team noted that the serial gastric specimens, taken before and after celecoxib therapy, were immunochemically stained for COX-2.
|All enrolled patients had no renal impairment during follow-up|
The intention-to-treat and per-protocol analyses to the rates of Intestinal metaplasia regression were higher in the celecoxib group than in the controls.
The doctors found that all enrolled patients had no renal impairment during follow-up.
Even in the patients without Intestinal metaplasia regression, the mean Intestinal metaplasia scores and COX-2 expressions were significantly more decreased in the celecoxib group than in the controls.
Dr Sheu's team commented "One year 200-mg celecoxib daily be safely administered to improve the regression or prevent the progression of persistent Intestinal metaplasia after H. pylori eradication."